Background Inhibitors of the anaplastic lymphoma kinase (ALK) gene mutation are highly
effective treatments for ALK-positive lung cancer. We conducted this pharmacovigilance …

Non-small-cell lung cancer (NSCLC) is frequently diagnosed when it is not amenable to
local therapies; therefore, systemic agents are the mainstay of therapy for many patients. In …

Lung cancer is the leading cause of deaths due to cancer in France. More than half of lung
cancers are discovered at an advanced-stage. New anticancer treatment strategies (ie, the …

Interventions: Osimertinib treatment was discontinued, and prednisolone (160 mg/day) and
supportive treatment were administered. Outcomes: The bilateral pneumothorax was difficult …

Although bevacizumab has several adverse effects, pneumothorax is rare. This is the first
case of initial treatment using an Endobronchial Watanabe Spigot (EWS) for pneumothorax …

Anlotinib is a multi‑target tyrosine kinase inhibitor and has been approved for the treatment
of patients with advanced non‑small cell lung cancer. The most common adverse events of …

An inflammatory myofibroblastic tumor (IMT) is an uncommon sarcoma subtype with
histopathological features, including inflammatory infiltrates. Anaplastic lymphoma kinase …

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are widely used in
patients with EGFR‐mutant lung cancer. Meanwhile, thermal ablation such as microwave …

Лекарственно-индуцированное поражение плевры (ЛИПП) может быть как
изолированным состоянием, так и сопутствующим при паренхиматозных заболеваниях …

Background The optimal strategy for the treatment of recurrent and/or advanced endometrial
cancer is still undefined. Recently, despite the lack of any predictive biomarker, the …